- Home
- ABP vs GOVX Comparison
ABP vs GOVX Comparison
Compare ABP & GOVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ABP
- GOVX
- Stock Information
- Founded
- ABP 2004
- GOVX 2001
- Country
- ABP United States
- GOVX United States
- Employees
- ABP N/A
- GOVX N/A
- Industry
- ABP Biotechnology: Pharmaceutical Preparations
- GOVX Biotechnology: Pharmaceutical Preparations
- Sector
- ABP Health Care
- GOVX Health Care
- Exchange
- ABP Nasdaq
- GOVX Nasdaq
- Market Cap
- ABP 15.5M
- GOVX 15.5M
- IPO Year
- ABP N/A
- GOVX N/A
- Fundamental
- Price
- ABP $0.21
- GOVX $0.95
- Analyst Decision
- ABP Strong Buy
- GOVX Strong Buy
- Analyst Count
- ABP 1
- GOVX 5
- Target Price
- ABP $4.00
- GOVX $12.40
- AVG Volume (30 Days)
- ABP 5.6M
- GOVX 1.5M
- Earning Date
- ABP 08-18-2025
- GOVX 08-05-2025
- Dividend Yield
- ABP N/A
- GOVX N/A
- EPS Growth
- ABP N/A
- GOVX N/A
- EPS
- ABP N/A
- GOVX N/A
- Revenue
- ABP $183,000.00
- GOVX $5,591,576.00
- Revenue This Year
- ABP N/A
- GOVX N/A
- Revenue Next Year
- ABP N/A
- GOVX N/A
- P/E Ratio
- ABP N/A
- GOVX N/A
- Revenue Growth
- ABP 88.66
- GOVX N/A
- 52 Week Low
- ABP $0.15
- GOVX $0.73
- 52 Week High
- ABP $11.19
- GOVX $11.18
- Technical
- Relative Strength Index (RSI)
- ABP N/A
- GOVX 46.22
- Support Level
- ABP N/A
- GOVX $0.85
- Resistance Level
- ABP N/A
- GOVX $1.39
- Average True Range (ATR)
- ABP 0.00
- GOVX 0.15
- MACD
- ABP 0.00
- GOVX -0.02
- Stochastic Oscillator
- ABP 0.00
- GOVX 18.52
About ABP Abpro Holdings Inc Common Stock
Abpro Holdings Inc is a biotechnology company dedicated to developing next-generation antibody therapeutics with the goal of improving the lives of patients with severe and life-threatening diseases. It is focused on novel antibody constructs for immuno-oncology and ophthalmology. By leveraging its proprietary DiversImmune and MultiMabTM antibody discovery and engineering platforms. The company is developing a pipeline of next-generation antibodies, both independently and through collaborations with pharmaceutical and research institutions.
About GOVX GeoVax Labs Inc.
Geovax Labs Inc is a clinical-stage biotechnology company developing human vaccines and immunotherapies against infectious diseases and solid tumor cancers using novel proprietary platforms. GeoVax's product pipeline includes ongoing human clinical trials for a next-generation COVID-19 vaccine and a gene-directed therapy against head and neck cancers. Additional research and development programs include preventive vaccines against Monkeypox (MPox), hemorrhagic fever viruses (Ebola Zaire, Ebola Sudan, Marburg, and Lassa), and Zika virus, as well as immunotherapies for multiple solid tumors. The Company's key clinical program is GEO-CM04S1, a next-generation COVID-19 vaccine.